Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

European trust in AstraZeneca vaccine falls, opinion poll says

Published 22/03/2021, 00:12
© Reuters. France resumes the use of the AstraZeneca COVID-19 vaccine
PFE
-
AZN
-
MRNA
-

BRUSSELS (Reuters) - Fewer Europeans trust the AstraZeneca (NASDAQ:AZN) COVID-19 vaccine after several countries reported side-effects, such as blood clots, an opinion poll by YouGov showed on Monday, even though scientific studies have found it is safe and effective.

An increased number of French, German, Italian and Spanish adults said they considered the vaccine unsafe, YouGov found, although faith in other vaccines by Pfizer Inc (NYSE:PFE) and Moderna (NASDAQ:MRNA) Inc was unaffected.

"Not only have we seen considerable rises in those who consider it unsafe in the last two weeks in Europe, the AstraZeneca vaccine continues to be seen as substantially less safe than its Pfizer and Moderna counterparts," lead data journalist at YouGov Matt Smith said in a statement.

Sixty-one percent of French adults surveyed said the vaccine was unsafe, a rise of 18 percentage points compared to February, YouGov said.

Just over half of German adults surveyed said they thought the vaccine was unsafe, a rise of 15 percentage points compared to February, while 43% of Italians had serious doubts, an increase of almost a third.

Spain showed a similar increase to Italy in the level of concern, YouGov said. Only in Britain was trust in the vaccine stable.

While the European Medicines Agency (EMA) has investigated reports of unusual blood disorders in recipients of the AstraZeneca vaccine, it said last week the benefits outweighed the risks and continues to recommend its use.

This month a series of European countries, including France, Germany and Italy halted its use after Denmark and Norway reporting isolated cases of bleeding, blood clots and a lowplatelet count.

That was the latest setback in the European Union's troubled rollout of vaccines that has been dogged by delays.

As EU nations face a third wave of infections and their vaccination campaigns move more slowly than those of Britain and the United States, health experts have chided EU leaders for poor communication and said the vaccine AstraZeneca developed in partnership with Britain's Oxford University is safe.

© Reuters. France resumes the use of the AstraZeneca COVID-19 vaccine

YouGov pollster surveyed 1,672 British adults, 2,024 Germans, 1,022 French, 1,016 Italians, 1050 Spaniards, 1,004 Danes, and 1,017 Swedes between March 12 and March 18 2021.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.